147 related articles for article (PubMed ID: 28536414)
1. Enzyme-Linked Immunosorbent Spot Assay for the Detection of Wilms' Tumor 1-Specific T Cells Induced by Dendritic Cell Vaccination.
Higuchi Y; Koya T; Yuzawa M; Yamaoka N; Mizuno Y; Yoshizawa K; Hirabayashi K; Kobayashi T; Sano K; Shimodaira S
Biomedicines; 2015 Dec; 3(4):304-315. PubMed ID: 28536414
[TBL] [Abstract][Full Text] [Related]
2. Dendritic Cell-Based Adjuvant Vaccination Targeting Wilms' Tumor 1 in Patients with Advanced Colorectal Cancer.
Shimodaira S; Sano K; Hirabayashi K; Koya T; Higuchi Y; Mizuno Y; Yamaoka N; Yuzawa M; Kobayashi T; Ito K; Koizumi T
Vaccines (Basel); 2015 Dec; 3(4):1004-18. PubMed ID: 26690485
[TBL] [Abstract][Full Text] [Related]
3. Dendritic cell-based immunotherapy targeting Wilms' tumor 1 in patients with recurrent malignant glioma.
Sakai K; Shimodaira S; Maejima S; Udagawa N; Sano K; Higuchi Y; Koya T; Ochiai T; Koide M; Uehara S; Nakamura M; Sugiyama H; Yonemitsu Y; Okamoto M; Hongo K
J Neurosurg; 2015 Oct; 123(4):989-97. PubMed ID: 26252465
[TBL] [Abstract][Full Text] [Related]
4. Phase I/II clinical trial of a Wilms' tumor 1-targeted dendritic cell vaccination-based immunotherapy in patients with advanced cancer.
Zhang W; Lu X; Cui P; Piao C; Xiao M; Liu X; Wang Y; Wu X; Liu J; Yang L
Cancer Immunol Immunother; 2019 Jan; 68(1):121-130. PubMed ID: 30306202
[TBL] [Abstract][Full Text] [Related]
5. Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay.
Pass HA; Schwarz SL; Wunderlich JR; Rosenberg SA
Cancer J Sci Am; 1998; 4(5):316-23. PubMed ID: 9815296
[TBL] [Abstract][Full Text] [Related]
6. Validation of a HLA-A2 tetramer flow cytometric method, IFNgamma real time RT-PCR, and IFNgamma ELISPOT for detection of immunologic response to gp100 and MelanA/MART-1 in melanoma patients.
Xu Y; Theobald V; Sung C; DePalma K; Atwater L; Seiger K; Perricone MA; Richards SM
J Transl Med; 2008 Oct; 6():61. PubMed ID: 18945350
[TBL] [Abstract][Full Text] [Related]
7. Pilot study of WT1 peptide-pulsed dendritic cell vaccination with docetaxel in esophageal cancer.
Matsuda T; Takeuchi H; Sakurai T; Mayanagi S; Booka E; Fujita T; Higuchi H; Taguchi J; Hamamoto Y; Takaishi H; Kawakubo H; Okamoto M; Sunamura M; Kawakami Y; Kitagawa Y
Oncol Lett; 2018 Jul; 16(1):1348-1356. PubMed ID: 29963201
[TBL] [Abstract][Full Text] [Related]
8. Wilms' Tumour 1 (WT1) peptide vaccination in patients with acute myeloid leukaemia induces short-lived WT1-specific immune responses.
Uttenthal B; Martinez-Davila I; Ivey A; Craddock C; Chen F; Virchis A; Kottaridis P; Grimwade D; Khwaja A; Stauss H; Morris EC
Br J Haematol; 2014 Feb; 164(3):366-75. PubMed ID: 24422723
[TBL] [Abstract][Full Text] [Related]
9. Treatment with chemotherapy and dendritic cells pulsed with multiple Wilms' tumor 1 (WT1)-specific MHC class I/II-restricted epitopes for pancreatic cancer.
Koido S; Homma S; Okamoto M; Takakura K; Mori M; Yoshizaki S; Tsukinaga S; Odahara S; Koyama S; Imazu H; Uchiyama K; Kajihara M; Arakawa H; Misawa T; Toyama Y; Yanagisawa S; Ikegami M; Kan S; Hayashi K; Komita H; Kamata Y; Ito M; Ishidao T; Yusa S; Shimodaira S; Gong J; Sugiyama H; Ohkusa T; Tajiri H
Clin Cancer Res; 2014 Aug; 20(16):4228-39. PubMed ID: 25056373
[TBL] [Abstract][Full Text] [Related]
10. Dendritic Cells Pre-Pulsed with Wilms' Tumor 1 in Optimized Culture for Cancer Vaccination.
Koya T; Date I; Kawaguchi H; Watanabe A; Sakamoto T; Togi M; Kato T; Yoshida K; Kojima S; Yanagisawa R; Koido S; Sugiyama H; Shimodaira S
Pharmaceutics; 2020 Mar; 12(4):. PubMed ID: 32231023
[TBL] [Abstract][Full Text] [Related]
11. Precision and linearity targets for validation of an IFNgamma ELISPOT, cytokine flow cytometry, and tetramer assay using CMV peptides.
Maecker HT; Hassler J; Payne JK; Summers A; Comatas K; Ghanayem M; Morse MA; Clay TM; Lyerly HK; Bhatia S; Ghanekar SA; Maino VC; Delarosa C; Disis ML
BMC Immunol; 2008 Mar; 9():9. PubMed ID: 18366814
[TBL] [Abstract][Full Text] [Related]
12. Encouraging Clinical Evolution of a Pediatric Patient With Relapsed Diffuse Midline Glioma Who Underwent WT1-Targeting Immunotherapy: A Case Report and Literature Review.
Hashii Y; Oka Y; Kagawa N; Hashimoto N; Saitou H; Fukuya S; Kanegae M; Ikejima S; Oji Y; Ozono K; Tsuboi A; Sugiyama H
Front Oncol; 2020; 10():1188. PubMed ID: 32793489
[TBL] [Abstract][Full Text] [Related]
13. Establishment of a stable T lymphoma cell line transduced with HLA-A*24:02-restricted WT1-specific TCR genes and its application to antigen-specific immunomonitoring.
Watanabe K; Toji S; Ohtake J; Nakano K; Satoh T; Kitamura H; Nishimura T
Biomed Res; 2013 Feb; 34(1):41-50. PubMed ID: 23428979
[TBL] [Abstract][Full Text] [Related]
14. Rapid monitoring of immune reconstitution after allogeneic stem cell transplantation--a comparison of different assays for the detection of cytomegalovirus-specific T cells.
Abu-Khader A; Krause S
Eur J Haematol; 2013 Dec; 91(6):534-45. PubMed ID: 23952609
[TBL] [Abstract][Full Text] [Related]
15. Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1 ) product.
Oka Y; Elisseeva OA; Tsuboi A; Ogawa H; Tamaki H; Li H; Oji Y; Kim EH; Soma T; Asada M; Ueda K; Maruya E; Saji H; Kishimoto T; Udaka K; Sugiyama H
Immunogenetics; 2000 Feb; 51(2):99-107. PubMed ID: 10663572
[TBL] [Abstract][Full Text] [Related]
16. [Immunotherapy for leukemia cells by using cytotoxic T lymphocyte specifically against WT1-derived peptide: an experimental study in vitro].
Gu WY; Cao XS; Qiu GQ; Chen ZX; Sheng LX; Xie XB; He J; Cen JN; Shen HL
Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(49):3475-80. PubMed ID: 16686063
[TBL] [Abstract][Full Text] [Related]
17. The Wilms' tumor antigen is a novel target for human CD4+ regulatory T cells: implications for immunotherapy.
Lehe C; Ghebeh H; Al-Sulaiman A; Al Qudaihi G; Al-Hussein K; Almohareb F; Chaudhri N; Alsharif F; Al-Zahrani H; Tbakhi A; Aljurf M; Dermime S
Cancer Res; 2008 Aug; 68(15):6350-9. PubMed ID: 18676860
[TBL] [Abstract][Full Text] [Related]
18. Detection of Wilms' tumor antigen--specific CTL in tumor-draining lymph nodes of patients with early breast cancer.
Gillmore R; Xue SA; Holler A; Kaeda J; Hadjiminas D; Healy V; Dina R; Parry SC; Bellantuono I; Ghani Y; Coombes RC; Waxman J; Stauss HJ
Clin Cancer Res; 2006 Jan; 12(1):34-42. PubMed ID: 16397021
[TBL] [Abstract][Full Text] [Related]
19. Induction of Immune Response after Allogeneic Wilms' Tumor 1 Dendritic Cell Vaccination and Donor Lymphocyte Infusion in Patients with Hematologic Malignancies and Post-Transplantation Relapse.
Shah NN; Loeb DM; Khuu H; Stroncek D; Ariyo T; Raffeld M; Delbrook C; Mackall CL; Wayne AS; Fry TJ
Biol Blood Marrow Transplant; 2016 Dec; 22(12):2149-2154. PubMed ID: 27634018
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
